Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
Lung cancer is the second most commonly diagnosed cancer and was the leading cause of cancer death in 2023 [1]. Non-small cell lung cancer (NSCLC) is the most common histopathological type, constituting almost 85  % of all lung cancer cases [2]. Only 20–25 % of patients are eligible for surgery, and surgical resection remains the mainstay treatment for resectable NSCLC [3]. Despite undergoing surgery, patients remain at high risk for recurrence and death after surgery. Neoadjuvant chemotherapy or adjuv ant chemotherapy improves the 5-year survival rate by only about 5 % [4]. (Source: Lung Cancer)
Source: Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Shu-Ling Zhang, Yuan Tian, Jing Yu, Jie-Hui Zhang, Li Sun, Le-Tian Huang, Jie-Tao Ma, Cheng-Bo Han Source Type: research
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
In non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations, exon 20 in-frame insertions (Exon20ins) are the third most common type of mutations, and is estimated to occur in 4  %–12 % of patients [1,2]. Previous studies have reported poor outcomes in NSCLC patients with EGFR Exon20ins treated with tyrosine-kinase inhibitors approved for NSCLC with common EGFR mutations (classical TKIs), suggesting that the development of targeted therapy for NSCLC patients harboring EGFR Exon20ins is an unmet need [3,4,5,6]. (Source: Lung Cancer)
Source: Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu Tags: Research Paper Source Type: research
Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma
Rearrangements/fusions involving the anaplastic lymphocyte kinase (ALK) gene occur in 3% to 7% of non-small cell lung carcinoma (NSCLC) cases [1]. Various ALK fusion variants, including EML4, KIF5B, TFG, KLC1, among others, have been identified in NSCLC [2]. Here, we present a case of a novel ALK fusion partner, protein kinase C epsilon (PRKCE), in a patient with NSCLC who exhibited a positive response to the ALK inhibitor ensartinib. (Source: Lung Cancer)
Source: Lung Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Lan Wang, Lei Li, Xue Zhou, Dongdong Zhang Source Type: research
The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population
With an estimated 2.2 million new cases and 1.8 million deaths in 2020, lung cancer accounts for approximately 1 in 10 cancers cases and 1 in 5 cancer deaths worldwide[1]. Precision oncology enables targeted therapies to decrease tumor burden and symptoms, and improve survival outcomes and quality of life for patients with specific oncogenic driver alterations[2 –4]. There is an expanding list of approved targeted therapies for clinically actionable biomarkers, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) and Proto-oncogene tyrosine-protein kinase (ROS1) rearrangements, re...
Source: Lung Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Sibo Liu, Nicholas Graves, Aaron C. Tan Tags: Research Paper Source Type: research
Trends and predictors of Quality of Life in lung cancer survivors
Health-related quality of life (HR-QoL) in lung cancer survivors is often impaired but infrequently recognized or treated [1,2]. Compared to other cancer types, patients with lung cancer struggle with worsened general health, heavier symptom burden, and HR-QoL impairment that is more common and often more severe [3,4]. For perspective,>90  % of patients with stage IV non-small cell lung cancer (NSCLC) report moderate-to-severe symptoms during their cancer course [5]. Compared to the general population, nearly all aspects of HR-QoL are lower in NSCLC survivors [6], and HR-QoL impairments have been reported in at least 20â...
Source: Lung Cancer - April 14, 2024 Category: Cancer & Oncology Authors: Brett C Bade, Julian Zhao MSPH, Fangyong Li MPH, Lynn Tanoue MD, Heather Lazowski, Catherine M Alfano, Gerard A Silvestri, Melinda L Irwin PhD Tags: Research Paper Source Type: research
The optimal treatment for patients with stage I non-small cell lung cancer: Minimally invasive lobectomy versus stereotactic ablative radiotherapy – A nationwide cohort study
Over the past decades, the optimal treatment for stage I non-small cell lung cancer (NSCLC) has been subject of debate. For operable patients, a lobectomy with systematic lymph node dissection, preferably minimally invasive by video-assisted thoracoscopic surgery (VATS), is recommended by (inter)national guidelines [1 –3]. However, since encouraging results have been obtained with stereotactic ablative radiotherapy (SABR) in inoperable patients, SABR is increasingly being used in operable patients as well [4,5], despite minimal evidence of equipoise between the two treatment modalities. (Source: Lung Cancer)
Source: Lung Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink, on behalf of the ESLUNG group Source Type: research
Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma
Lung cancer is the leading cause of cancer-related mortality worldwide [1]. With the popularity of low-dose computed tomography (CT) screening, more and more early-stage lung cancers were being diagnosed. Flores et al. found a stage shift from later to earlier stage disease among people with lung cancer over the last decade. From 2006 to 2016, stage I-II lung cancer diagnoses increased from 26.5  % to 31.2 %, and stage III-IV diagnoses decreased from 70.8 % to 66.1 % [2]. The majority of patients diagnosed with low-dose CT were in the earlier stage. (Source: Lung Cancer)
Source: Lung Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Yueh-Feng Lu, Ya-Hsuan Chang, Yi-Ju Chen, Min-Shu Hsieh, Mong-Wei Lin, Hsao-Hsun Hsu, Chia-Li Han, Yu-Ju Chen, Sung-Liang Yu, Jin-Shing Chen, Hsuan-Yu Chen Source Type: research
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death protein –ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) antibodies, have been approved for patients with advanced or recurrent non-small cell lung cancer (NSCLC) [1–9]. However, ICIs often cause immune-related adverse events (irAEs), potentially leading to discontinuation of the treatment. A meta-analysis demonstrated that treatment discontinuation due to irAE may affect the outcome of the patient [10]. (Source: Lung Cancer)
Source: Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Mina Ishidoya, Tomonori Makiguchi, Hisashi Tanaka, Toko Miura, Yasuhito Nunomura, Dai Miura, Takeshi Morimoto, Yukihiro Hasegawa, Kageaki Taima, Sadatomo Tasaka Tags: Research Paper Source Type: research
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene i.e., the KRASG12C mutation, detected in 13  % of the cases [1]. (Source: Lung Cancer)
Source: Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Ali Chour, Cl émence Basse, Fanny Lebossé, Pierre-Emmanuel Bonte, Nicolas Girard, Michaël Duruisseaux Source Type: research
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibodies, form the standard of care in advanced lung cancer. PD-L1 expression status on tumor (TCs) and immune (ICs) cells, as measured by immunohistochemistry (IHC), is a predictive biomarker of the efficacy of PD-1/PD-L1 blockade therapy [1 –3]. Multiple assays have been developed to evaluate PD-L1 expression in conjunction with a particular therapeutic agent. For advanced non-small cell lung cancer (NSCLC), the FDA has approved four assays as companion diagnostics (CDxs), viz., PD-L1 IHC 2...
Source: Lung Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Jun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Noboru Yamamoto, Yasushi Yatabe, Takuji Suzuki Tags: Research Paper Source Type: research
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database
In the era of precision medicine an increasing number of predictive biomarkers was clinically approved by international scientific societies to select advanced Non-Small Cell Lung Cancer (NSCLC) patients who are eligible for targeted therapies [1 –3]. In this rapidly evolving scenario, a plethora of diagnostic specimens must be available for both morphological and molecular evaluation in order to optimize the therapeutic management of NSCLC patients [4,5] Of note, adequacy of tissue samples represents one of the main gaps limiting biomarke r testing in metastatic NSCLC, because scant biological specimens occur in a not n...
Source: Lung Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Umberto Malapelle, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Maria Lucia Reale, Diego Cortinovis, Filippo Fragetta, Domenico Galetta, Edoardo Garbo, Paolo Graziano, Fabio Pagni, Giulia Pasello, Pierluigi Piovano, Sara Pilotto, Marcello Tiseo, Tags: Research Paper Source Type: research
Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?
A number of retrospective studies have reported that non-small cell lung cancer (NSCLC) patients with immune-related adverse events (irAEs) have a better prognosis. Most recently, this was demonstrated in a pooled analysis of the IMPOWER130, 132, and 150 trials [1]. However, this paper also showed that the incidence of grade 3 or higher irAEs was associated with a poor prognosis [1], so it is questionable whether the incidence of irAEs themselves is a prognostic factor. Recently, genetic analysis using genome-wide association studies revealed that expression of the rs16906115 gene, located near interleukin-7, is involved i...
Source: Lung Cancer - April 3, 2024 Category: Cancer & Oncology Authors: Tadashi Nishimura, Hajime Fujimoto Source Type: research
Title Page
(Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Source Type: research
Editorial Board
(Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Source Type: research
Contents
(Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Source Type: research
